Month: February 2024

Zerify Dominates New HIPAA Cybersecurity Guidance, Standing Alone as the Unrivaled Market Leader in Key Areas

Written by Customer Service on February 22, 2024. Posted in Public Companies.

EDISON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) — Zerify Inc. (OTC PINK: ZRFY), a leading cybersecurity firm specializing in secure video conferencing and endpoint security, is pleased to announce that it has solidified its position as the foremost provider of HIPAA-compliant cybersecurity technologies, eclipsing competitors and setting new benchmarks in the industry. With the recent release of the National Institute of Standards and Technology’s (NIST) updated cybersecurity guidance for HIPAA compliance, Zerify’s suite of solutions stands alone in meeting and exceeding the stringent requirements set forth by the regulatory authorities. NIST’s latest cybersecurity guidance for HIPAA underscores the critical need for safeguarding electronic protected health information (ePHI) held or maintained by regulated entities....

Form 8.3 – [ SHANTA GOLD LIMITED – 21 02 2024] – (CGAML)

Written by Customer Service on February 22, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree SHANTA GOLD LIMITED(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury

Written by Customer Service on February 22, 2024. Posted in Public Companies.

SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) Approval Order to the Selective Cytopheretic Device (SCD) Pediatric (SCD-PED) for use in children weighing 10 kilograms or more with acute kidney injury (AKI) due to sepsis or a septic condition requiring kidney replacement therapy (KRT). This is the first product in the Company’s newly branded Quelimmune product family, and the Quelimmune pediatric device can now be commercially marketed as a Humanitarian...

Form 8.3 – [ LONDONMETRIC PROPERTY PLC – 21 02 2024] – (CGWL)

Written by Customer Service on February 22, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LONDONMETRIC PROPERTY PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Written by Customer Service on February 22, 2024. Posted in Public Companies.

Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression. The white paper summarizes the preclinical research of leading inflammasome experts, Drs. Robert W. Keane and Juan Pablo de Rivero Vaccari at University of Miami Miller School of Medicine, demonstrating that Inflammasome ASC Inhibitor IC 100 crosses the blood brain barrier, and that it displays strong pharmacologic and mechanistic proof-of-concept in a variety of neurological conditions.WESTON, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq:...

Save Foods: NTwo Off Filed US Patent Application to Reduce Greenhouse Gas Emissions in Wheat Production

Written by Customer Service on February 22, 2024. Posted in Public Companies.

Neve Yarak, Israel, Feb. 22, 2024 (GLOBE NEWSWIRE) — Save Foods, Inc. (NASDAQ: SVFD) (FSE:80W), a pioneer Agri-Food Tech company offering sustainable solutions for agriculture and plant based food, announced the filing of a US patent application by its majority-owned subsidiary, NTwo Off Ltd. (“NTwo Off”, formerly Nitrousink Ltd.) on January 11, 2024, aimed at revolutionizing wheat production. The patent application represents NTwo Off’s goal to assist in mitigating the environmental impact of agriculture, specifically targeting the reduction of nitrous oxide (N2O) emissions in wheat farming. The patented technology refers to methodologies of effectively mitigating nitrous oxide emissions during wheat cultivation. By implementing this innovative approach, NTwo Off hopes to reduce farmers’ environmental footprint while enhancing...

The Shyft Group Reports Fourth Quarter and Full-Year 2023 Results

Written by Customer Service on February 22, 2024. Posted in Earnings Releases And Operating Results.

Generated free cash flow of $36 million in the year; improvement of $75 million year-over-year Delivered record profitability in Specialty Vehicles business Introduces 2024 outlook with sales of $850 to $900 million and adjusted EBITDA of $40 to $50 millionNOVI, Mich., Feb. 22, 2024 (GLOBE NEWSWIRE) — The Shyft Group, Inc. (NASDAQ: SHYF) (“Shyft” or the “Company”), the North American leader in specialty vehicle manufacturing, assembly and upfit for the commercial, retail and service specialty vehicle markets, today reported operating results for the fourth quarter and full-year ending December 31, 2023. Fourth Quarter 2023 Financial Highlights For the fourth quarter of 2023 compared to the fourth quarter of 2022:Sales of $202.3 million, a decrease of $99.7 million, or 33.0%, from $302.0 million Net loss of $4.4 million,...

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Written by Customer Service on February 22, 2024. Posted in Dividend Reports And Estimates.

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $325.0 million, before deducting placement agent fees and other offering expenses. The private placement includes participation by new and existing investors, including Venrock Healthcare Capital Partners, TCGX, Deep Track Capital, Perceptive Advisors, Great Point Partners, LLC, Logos Capital, Surveyor Capital (a Citadel...

Brady Corporation Reports Fiscal 2024 Second Quarter Results and Raises the low end of its Fiscal 2024 Guidance

Written by Customer Service on February 22, 2024. Posted in Earnings Releases And Operating Results.

Sales for the quarter decreased 1.1 percent. Organic sales increased 1.6 percent, foreign currency translation increased sales 0.8 percent and divestitures decreased sales 3.5 percent. Gross profit margin increased to 50.2 percent in the second quarter of fiscal 2024 compared to 48.0 percent in the second quarter of fiscal 2023. Diluted EPS increased 18.4 percent to $0.90 in the second quarter of fiscal 2024 compared to $0.76 in the same quarter of the prior year. Diluted EPS Excluding Certain Items* increased 14.8 percent to $0.93 in the second quarter of fiscal 2024 compared to $0.81 in the same quarter of the prior year. Net cash provided by operating activities increased to $36.1 million in the second quarter of fiscal 2024 compared to $29.4 million in the second quarter of last year. The low end of the Earnings per diluted Class...

AppTech’s Strategic Partner InstaCash on Track to Launch Cutting Edge Peer-to-Peer Mobile Payments Platform Q2 2024: User Sign-Ups Available Now

Written by Customer Service on February 22, 2024. Posted in Public Companies.

Sign-up at www.instacash.cash for peer-to-peer payment solution that rivals Venmo, Zelle, and Cash App with lower fees and advanced security protocols CARLSBAD, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech”) (Nasdaq: APCX), a pioneering Fintech company powering frictionless commerce, today announced that its strategic partner, InstaCash, Inc. (“InstaCash”) has gone live with its new www.instacash.cash website. InstaCash is now enrolling initial users for the upcoming launch of its innovative mobile-to-mobile payment system build on AppTech’s patented FinZeo™ platform. With an anticipated market launch by the end of Q2 2024, InstaCash, a peer-to-peer instant payment app similar to Venmo, Zelle, and Cash App, will offer a better cutting-edge user-friendly product with lower transfer fees and more...

Month: February 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals